Insider Trading Alert - ENTA, ATSG And RGR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 20, 2015, 100 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $186.58 to $190,703,600.00.

Highlighted Stocks Traded by Insiders:

Enanta Pharmaceuticals (ENTA) - FREE Research Report

Mellett Paul J, who is Treasurer and CFO at Enanta Pharmaceuticals, sold 24,000 shares at $40.13 on May 20, 2015. Following this transaction, the Treasurer and CFO owned 97,897 shares meaning that the stake was reduced by 19.69% with the 24,000-share transaction.

The shares most recently traded at $40.68, up $0.55, or 1.35% since the insider transaction. Historical insider transactions for Enanta Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 8,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 23,000
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 57,500

The average volume for Enanta Pharmaceuticals has been 318,300 shares per day over the past 30 days. Enanta Pharmaceuticals has a market cap of $753.8 million and is part of the health care sector and drugs industry. Shares are down 20.26% year-to-date as of the close of trading on Wednesday.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. The company has a P/E ratio of 6.7. Currently, there are 3 analysts who rate Enanta Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENTA - FREE

TheStreet Quant Ratings rates Enanta Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has experienced relatively poor performance when compared with the S&P 500 during the past year. Get the full Enanta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Air Transport Services Group (ATSG) - FREE Research Report

Manibusan Dennis A, who is Subsidiary President - ATI at Air Transport Services Group, sold 4,671 shares at $10.88 on May 20, 2015. Following this transaction, the Subsidiary President - ATI owned 52,732 shares meaning that the stake was reduced by 8.14% with the 4,671-share transaction.

Historical insider transactions for Air Transport Services Group go as follows:

  • 4-Week # shares sold: 22,594
  • 12-Week # shares sold: 30,094
  • 24-Week # shares sold: 60,094

The average volume for Air Transport Services Group has been 286,900 shares per day over the past 30 days. Air Transport Services Group has a market cap of $702.6 million and is part of the services sector and transportation industry. Shares are up 25.82% year-to-date as of the close of trading on Wednesday.

Air Transport Services Group, Inc., through its subsidiaries, provides airline operations, aircraft leasing and maintenance, and other support services primarily to the air cargo transportation and package delivery industries in the United States and internationally. The company has a P/E ratio of 20.3. Currently, there are 3 analysts who rate Air Transport Services Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ATSG - FREE

TheStreet Quant Ratings rates Air Transport Services Group as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Air Transport Services Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Sturm Ruger (RGR) - FREE Research Report

Jacobi C Michael, who is Director at Sturm Ruger, sold 2,124 shares at $55.27 on May 20, 2015. Following this transaction, the Director owned 11,766 shares meaning that the stake was reduced by 15.29% with the 2,124-share transaction.

The shares most recently traded at $55.12, down $0.16, or 0.28% since the insider transaction. Historical insider transactions for Sturm Ruger go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares sold: 2,000

The average volume for Sturm Ruger has been 284,500 shares per day over the past 30 days. Sturm Ruger has a market cap of $1.0 billion and is part of the industrial goods sector and aerospace/defense industry. Shares are up 59.89% year-to-date as of the close of trading on Wednesday.

Sturm, Ruger & Company, Inc. designs, manufactures, and sells firearms under the Ruger trademark in the United States. The stock currently has a dividend yield of 1.95%. The company has a P/E ratio of 35.9. Currently, there are 2 analysts who rate Sturm Ruger a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RGR - FREE

TheStreet Quant Ratings rates Sturm Ruger as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sturm Ruger Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Strong On High Relative Volume: Enanta Pharmaceuticals (ENTA)

Strong On High Relative Volume: Enanta Pharmaceuticals (ENTA)

Insider Trading Alert - ENTA, EBIO And PSEC Traded By Insiders

Insider Trading Alert - ENTA, EBIO And PSEC Traded By Insiders

5 Hated Stocks You Should Love

5 Hated Stocks You Should Love

Insider Trading Alert - ENTA, HBI And MOFG Traded By Insiders

Insider Trading Alert - ENTA, HBI And MOFG Traded By Insiders

Enanta Pharmaceuticals (ENTA) Showing Signs Of Perilous Reversal Today

Enanta Pharmaceuticals (ENTA) Showing Signs Of Perilous Reversal Today